interferon gamma (ifnγ)-primed human bone marrow-derived mesenchymal stromal cells
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2020 (NCT04328714)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05035862 | Phase 1 | Jan 31, 2022 | Emory University, The Marcus Foundation |
| NCT04489732 | Phase 1 | Dec 31, 2021 | National Institute of Dental and Craniofacial Research (NIDCR), University of Wisconsin |
| NCT04328714 | Phase 1 | Aug 31, 2020 | Emory University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emory University | Academic/Hospital | 2 | 2 | 1 | 2020 |
| National Institute of Dental and Craniofacial Research (NIDCR) | Government | 1 | 0 | 1 | 2021 |
| The Marcus Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1